The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis

Abstract

Objective The primary objective of this study was to develop a quantitative test to assess ambulation in multiple sclerosis (MS) patients that is more accurate and sensitive than the Timed 25-foot walk (T25FW). For this purpose, we developed the Six Spot Step Test (SSST), which besides speed includes co-ordination and balance, to be a lower limb counterpart to the 9-Hole Peg Test (9HPT).

Background The T25FW, which is the ambulation test of the MS Functional Composite (MSFC), reflects only the speed component of walking. The lack of sensitivity to other components of gait adds to the floor effect.

Methods and patients In the SSST, the patient is instructed to walk as quickly as possible from one end to the other of a rectangular field measuring 1× 5 m, while kicking five cylinder blocks out of five circles marked on the floor. Some 151 MS patients with the Expanded Disability Status Scale (EDSS) score 0-6.5 and 64 normal controls performed the SSST and the T25FW. In addition, 41 patients performed the tests twice.

Results The range of the SSST (4.7-35.1 seconds) was wider than that of the T25FW (3.5-22.6 seconds). Using control mean+ 2 SD as cut off, 107 patients had abnormal SSST, while 100 patients had abnormal T25FW. The T25FW (mean) increased 2.1 seconds over the EDSS range of 0-4.0, while the SSST increased 4.9 seconds. The intra-class correlation between repeated tests (r) was 0.95 for the SSST and 0.96 for the T25FW. The correlation between the SSST and the T25FW was high (r=0.92).

Conclusion The SSST seems to be superior to the T25FW in terms of dynamic range, floor effect and discriminatory power. The SSST is a relevant alternative for the T25FW as the ambulation component of the MSFC.

Keywords

ambulation clinical assessment EDSS MSFC MSIS multiple sclerosis outcome measure SSST

Get full access to this article

View all access options for this article.

References

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

Amato MP , Fratiglioni L , Groppi C , Siracusa G , Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis . Arch Neurol 1988; 45: 746-748 .

Noseworthy JH , Vandervoort MK , Wong CJ , Ebers GC and the Canadian Cooperative MS Study Group . Interrater variability with Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial . Neurology 1990; 40: 971-975 .

Whitaker JN , McFarland HF , Rudge P , Reingold SC. Outcomes assessments in multiple sclerosis clinical trials: a critical analysis . Mult Scler 1995; 1: 37-46 .

Hobart JH , Freeman J , Thompson AJ. Kurtzke scales revisited: the application of psychometric methods to clinical intuition . Brain 2000; 123: 1027-1040 .

Rudick R , Antel J , Confraceux C , Cutter G , Ellison G , Fischer J et al. Recommendations from the National Multiple Sclerosis Society clinical outcomes assessment task force . Ann Neurol 1997; 42: 397-482 .

Cutter GR , Baier ML , Rudick RA. Development of a multiple sclerosis functional composite (MSFC) as a clinical trial outcome measure . Brain 1999; 122: 871-882 .

Rudick RA , Cutter GR. Use of the multiple sclerosis functional composite (MSFC) to predict disability in relapsing MS . Neurology 2001; 56: 1324-1330 .

Rudick RA , Cutter GR , Reingold S. The multiple sclerosis functional composite (MSFC): a new clinical outcome measure for multiple sclerosis . Mult Scler 2002; 8: 359-365 .

10.

Miller DM , Rudick RA. Clinical significance of the multiple sclerosis functional composite (MSFC): relationship to patient-reported quality of life . Arch Neurol 2000; 57: 1319-1324 .

11.

Kalkers NF , Groot de V. Multiple sclerosis functional composite (MSFC): relation to disease phenotype and disability strata . Neurology 2000; 54: 1233-1239 .

12.

Cohen JA , Fischer JS , Cutter GR. Intrarater and interrater reliability of the multiple sclerosis functional composite (MSFC) outcome measure . Neurology 2000; 54: 802-806 .

13.

Cohen JA , Cutter GR , Fischer JS , Goodman AD. Benefit of interferon B-1a on multiple sclerosis functional composite (MSFC) progression in secondary progressive MS . Neurology 2002; 59: 679-687 .

14.

Hoogervorst ELJ , Kalkers NF , Uitdehaag BMJ , Polman CH. A study validating changes in the multiple sclerosis functional composite (MSFC) . Arch Neurol 2002; 59: 113-116 .

15.

Cohen JA , Cutter GR. Use of the multiple sclerosis functional composite (MSFC) as an outcome measure in a phase-3 clinical trial . Arch Neurol 2001; 58: 961-967 .

16.

Fischer JS , Rudick RA , Cutter GR. The multiple sclerosis functional composite (MSFC) measure: an integrated approach to MS clinical outcome assessment . Mult Scler 1999; 5: 244-250 .

17.

Kalkers NF , Bergers L. Concurrent validity of the multiple sclerosis functional composite (MSFC) using MRI as a biological marker . Neurology 2001; 56: 215-219 .

18.

Hobart JC , Riazi A , Lamping DL , Fitzpatrick R , Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12) . Neurology 2003; 60: 31-36 .

19.

Ravnborg M , Grønbech-Jensen M , Jønsson A. The MS-impairment scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis . Mult Scler 1997; 3(1): 31-42 .

20.

Ravnborg M , Blinkenberg M , Sellebjerg F , Ballegaard M , Larsen SH , Sorensen PS. Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale . Mult Scler 2005; 11(1): 81-84 .